| Congenital agammaglobulinemia
Gammaplex vs Octagam 5%
Side-by-side clinical, coverage, and cost comparison for congenital agammaglobulinemia.Deep comparison between: Gammaplex vs Octagam Immune Globulin (Human) with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOctagam Immune Globulin (Human) has a higher rate of injection site reactions vs Gammaplex based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Octagam Immune Globulin (Human) but not Gammaplex, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Gammaplex
Octagam Immune Globulin (Human)
At A Glance
IV infusion
Every 3-4 weeks
Immune globulin (IgG replacement)
IV infusion
Every 3-4 weeks
Intravenous immunoglobulin (IVIG)
Indications
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Congenital agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Immune thrombocytopenic purpura
- Congenital agammaglobulinemia
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
Dosing
Common Variable Immunodeficiency, X-linked agammaglobulinemia, Congenital agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency 300-800 mg/kg (3-8 mL/kg) IV every 3-4 weeks; initial infusion rate 0.5 mg/kg/min for 15 minutes, then increase gradually every 15 minutes to 8 mg/kg/min.
Immune thrombocytopenic purpura 1 g/kg (10 mL/kg) IV on 2 consecutive days (total dose 2 g/kg); initial infusion rate 0.5 mg/kg/min for 15 minutes, then increase gradually every 15 minutes to 8 mg/kg/min.
Congenital agammaglobulinemia, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency 300-600 mg/kg IV every 3-4 weeks; adjust dose over time to achieve desired trough levels and clinical response.
Measles Exposure 400 mg/kg IV as soon as possible and within 6 days of exposure; increase to at least 530 mg/kg every 3-4 weeks if patient is at risk of future measles exposure.
Contraindications
- Previous anaphylactic or severe systemic reaction to human immune globulin
- IgA deficiency with antibodies to IgA and a history of hypersensitivity
- Acute severe hypersensitivity reaction to human immunoglobulin
- IgA deficiency with antibodies against IgA and history of hypersensitivity
- Acute hypersensitivity reaction to corn (product contains maltose derived from corn)
Adverse Reactions
Most common (>=5%) in PI Headache, migraine, pyrexia
Most common (>=5%) in ITP Headache, vomiting, pyrexia, nausea, arthralgia, dehydration
Serious Thrombotic events, hemolysis; in ITP subjects: headache, vomiting, dehydration
Postmarketing Tachycardia, thromboembolism, hypertension, flushing, nausea, chills, chest discomfort, pyrexia, back pain, polymyositis, headache, dyspnea, rash, urticaria
Most common (>=5%) headache, nausea
Serious anaphylactic reactions, thromboembolic events, aseptic meningitis, hemolytic anemia
Postmarketing leukopenia, hemolytic anemia, anaphylactic shock, angioedema, cerebrovascular accident, myocardial infarction, pulmonary embolism, renal failure acute, transfusion-related acute lung injury
Pharmacology
Polyclonal human IgG that provides replacement therapy for primary humoral immunodeficiency via a broad spectrum of opsonic and neutralizing IgG antibodies against pathogens and their toxins through antigen binding and effector functions; the mechanism of action in both PI and ITP has not been fully elucidated.
Intravenous immunoglobulin G preparation that supplies a broad spectrum of opsonic and neutralizing IgG antibodies against bacteria and their toxins; restores abnormally low IgG levels to the normal range in patients with primary humoral immunodeficiency.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Gammaplex
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Octagam Immune Globulin (Human)
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (7/12) · Qty limit (0/12)
UnitedHealthcare
Gammaplex
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (0/8)
Octagam Immune Globulin (Human)
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Gammaplex
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Octagam Immune Globulin (Human)
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Gammaplex.
No savings programs available for Octagam Immune Globulin (Human).
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
GammaplexView full Gammaplex profile
Octagam Immune Globulin (Human)View full Octagam Immune Globulin (Human) profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.